Live Evaluations
What you Need to Know NOW about Actinic Keratosis
About
What you Need to Know NOW about Actinic Keratosis
This activity is supported by educational grants from Almirall, LLC and Biofrontera.
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify the various therapies available for the management of actinic keratosis
Define expert recommended approaches for integrating actinic keratosis therapies into practice
Intended Audience
Faculty
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Advisory Board/Consultant: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
Grant/Research Support: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
Speaker's Bureau: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.